How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

43 results for

Cognex

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17

. Clinical diagnosis of Down syndrome (DS) - participants may have free trisomy 21, Robertsonian translocations, or mosaic DS. Naive to approved or unapproved cholinesterase inhibitors (Aricept, Exelon, Cognex, Reminyl/Razadyne, metrifonate, physostigmine) is preferred. However, prior use of these medications is allowed, provided that the medication was discontinued at least 3 months prior to screening and that it was not discontinued for lack of tolerability or efficacy or for the sole purpose

2008 Clinical Trials

22. Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10

. VABS-II/PCRF receptive sub-domain raw score of >= 25 and expressive sub-domain raw score of >= 61. Clinical diagnosis of Down syndrome (DS) - subjects may have free trisomy 21, Robertsonian translocations, or mosaic DS Naive to approved or unapproved cholinesterase inhibitors (Aricept, Exelon, Cognex, Reminyl/Razadyne, metrifonate, physostigmine) is preferred. However, prior use of these medications is allowed, provided that the medication was discontinued at least 3 months prior to screening

2008 Clinical Trials

23. Targeting Inflammation Using Salsalate in CardioVascular Disease

(orlistat), Meridia (sibutramine), Acutrim (phenylpropanolamine) or similar over-the counter medications] within three months of screening Surgery within 30 days of screening History of acquired immune deficiency syndrome or human immunodeficiency virus (HIV) Poor mental function or history of dementia/ Alzheimer's Disease or on medications used for treatment of dementia [e.g. Tacrine (Cognex), Rivastigmine (Exelon), Galantamine (Razadyne, Reminyl), Donepezil (Aricept), Memantine (Namenda)] or any other

2008 Clinical Trials

24. Evaluation of [123I] AV94 and SPECT in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

. Pregnancy Concomitant therapy Patients may remain on a stable dose of anticholinesterase medication during the study. Use of donepezil (Aricept®), rivastigmine (Exelon®), galantamine (Razadyne®), tacrine (Cognex®), and memantine (Namenda®) are permitted during the study. Doses of these compounds must be stable for 2 months prior to the study. At each visit after the screening visit, the investigator will ask the patient whether any medications including OTC medications, were taken since the previous

2008 Clinical Trials

25. Evaluation of [123I] AV151 and SPECT in Subjects w/ AD in Comparison to Healthy Subjects

Concomitant therapy Patients may remain on a stable dose of anticholinesterase medication during the study. Use of donepezil (Aricept®), rivastigmine (Exelon®), galantamine (Razadyne®), tacrine (Cognex®), and memantine (Namenda®) are permitted during the study. Doses of these compounds must be stable for 2 months prior to the study. At each visit after the screening visit, the investigator will ask the patient whether any medications including OTC medications, were taken since the previous visit. Use

2008 Clinical Trials

26. Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease

. If there has been a significant change in clinical status suggestive of stroke or other possible neurological disease with onset between the time of the last CT or MRI and the screening evaluation, the scan should be repeated if considered appropriate by the investigator. Prior use of cholinesterase inhibitors (Aricept®, Exelon®, Cognex®, Reminyl/Razadyne®, metrifonate, physostigmine) and memantine is allowed, provided that the medication was discontinued at least 3 months prior to screening

2008 Clinical Trials

27. Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease

), memantine (Namenda™) or tacrine (Cognex®) taken within twelve (12) weeks of the Baseline Visit (Visit 2). Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00663936 Sponsors and Collaborators FUJIFILM Toyama Chemical Co., Ltd. More Information Go

2008 Clinical Trials

28. EARTH 413: A Study of Aricept in Hispanic Patients With Mild to Moderate Alzheimer's Disease (AD)

(Exelon® , Cognex®, Reminyl®/Razadyne®, metrifonate, physostigmine) or memantine is allowed provided that the medication was discontinued at least 3 months prior to screening and that the discontinuation was not done for the purpose of enrolling the patient in this trial. Patients must reside in the community. (Residence in an assisted living facility is allowed.) Patients must have a reliable caregiver or family member who agrees to accompany the patient to all clinic visits, provide information

2005 Clinical Trials

29. Donepezil Hydrochloride (E2020) in Dementia Associated With Cerebrovascular Disease

. Patients receiving anticoagulation with warfarin are eligible for inclusion in the study if the International Normalized Ratio (INR) for prothrombin time is within the therapeutic range for prophylaxis (1.4-3.0) and the dose of warfarin is stable. -- Patients with prosthetic heart valves, who require full anticoagulation, should have a stable (>= 3 months) INR in the range of 2.5-3.5. 9. Patients who have taken a previously approved cholinesterase inhibitor (e.g., Aricept., Exelon., Reminyl., Cognex

2005 Clinical Trials

30. Evaluation of 5-[123I]-A-85380 and SPECT Imaging in Individuals With Parkinsons Disease

clinical response to dopaminergic therapy treatment Hoehn and Yahr Stages < 3; 2-7 year Duration from time of diagnosis. Mini-mental status exam score of >24, For females, non-child bearing potential or negative urine pregnancy test on day of [123I] 5-IA injection. Exclusion Criteria: Secondary Parkinsonism; Nicotine dependence or use within the previous 12 months prior to enrollment; Treatment with Aricept (donepezil), Exelon (rivastigmine), Cognex (tacrine) within the past 30 days; treatment

2006 Clinical Trials

31. Treatment of Advanced Renal Cell Carcinoma With Quinacrine

of baseline visit. Subjects who have received any anticancer agents, treatment (chemotherapy, targeted agents, radiation, hormones), or investigational agents within 30 days of the baseline visit. Subjects who have untreated brain metastases. Subjects who have a history of hypersensitivity reaction to quinacrine or other acridine derivatives (e.g. Cognex). Subjects who have any clinically significant hematological, endocrine, cardiovascular (including any rhythm disorder), renal, hepatic, gastrointestinal

2007 Clinical Trials

32. The Effectiveness And Safety Of Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living Facility

to a skilled nursing home during this study will be discontinued. Subjects who have taken the following medications within the last 3 months prior to screening will be not eligible: Aricept, Exelon, Cognex, Razadyne, Metrifonate, Namenda or propentofylline. Subjects without a reliable caregiver/informant or subjects whose caregiver is unwilling or unable to complete the outcome measures and fulfill the requirements of this study. Subjects with clinically significant obstructive pulmonary disease or asthma

2007 Clinical Trials

33. Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP)

Visit. Physically acceptable for this study as confirmed by medical history, physical exam and clinical laboratory tests. Must be able to ingest oral medications. Supervision must be available for administration of study medication. Taking any marketed cholinesterase inhibitor (donepezil [Aricept], rivastigmine [Exelon], galantamine [Reminyl], tacrine [Cognex], and/or memantine at a dose unchanged for at least 2 weeks prior to the screening visit. Participants may reside in their own home

2002 Clinical Trials

34. Gene Therapy for Alzheimer's Disease Clinical Trial

stage of Alzheimer's disease (generally within three years of onset) Normal speaking ability and normal ability to understand Ability to understand the potential risks of participation in this study Willing to visit the San Diego area and be available for many visits in the first year Willing to discontinue use of drugs Cognex, Aricept, Exelon, or Reminyl for the first 18 months of the trial Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study

2001 Clinical Trials

35. Nefiracetam in the Treatment of Alzheimer's Disease

history of schizophrenia. No substance use disorder within 1 year of dementia onset. No depression requiring medical treatment within the past 30 days. No administration of tacrine (Cognex) or donezepil (Aricept), investigational drugs, or nutritional supplements used as neurotransmitter precursors for cognitive enhancement within 30 days before enrollment. No use of anticonvulsants, psychostimulants, centrally acting anticholinergics and agents known to inhibit or be metabolized by CYP 3A4 (e.g

1999 Clinical Trials

36. Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)

or anxiety disorder but completed treatment more than four months ago is eligible.]; The participant must not currently use of any of the following medications: Aricept, Cognex, Exelon, Reminyl, or Hydergine; The participant must not have blindness, deafness, language difficulties or any other disability that may prevent completion of the memory screen. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study

2002 Clinical Trials

37. The temporal effect of food on tacrine bioavailability. (PubMed)

The temporal effect of food on tacrine bioavailability. A four-way cross-over study was performed to assess the temporal effect of food on the rate and extent of tacrine (Cognex, THA) absorption after drug administration to healthy, older volunteers. Each volunteer received four single 40-mg THA doses at 1-week intervals. Doses were administered after an 8-hour overnight fast, 1 hour before a standard breakfast, 15 minutes after beginning a standard breakfast, and 2 hours after completion

1994 Journal of clinical pharmacology

38. Safety of tacrine: clinical trials, treatment IND, and postmarketing experience. (PubMed)

Safety of tacrine: clinical trials, treatment IND, and postmarketing experience. The safety of tacrine (Cognex), a centrally active, reversible acetylcholinesterase inhibitor approved in 1993 for the treatment of mild to moderate dementia of the Alzheimer type, was evaluated in 2,706 patients with Alzheimer disease (AD) in clinical trials and in 9861 patients with AD in a treatment investigational new drug (TIND) program. More than 190,000 patients in the United States received tacrine during

1998 Alzheimer disease and associated disorders

39. Evaluation of tacrine hydrochloride (Cognex) in two parallel-group studies. (PubMed)

Evaluation of tacrine hydrochloride (Cognex) in two parallel-group studies. The efficacy of tacrine hydrochloride (Cognex) for the treatment of Alzheimer's disease (AD) has been confirmed in two randomized, double-blind, placebo-controlled, parallel-group studies. More than 1100 patients with mild to moderate, probable AD were randomized to receive placebo or tacrine for 12 or 30 weeks. Outcome measures included objective assessments of cognitive function, qualitative assessments of treatment

1996 Acta neurologica Scandinavica. Supplementum

40. Mixed-model analysis of incomplete longitudinal data from a high-dose trial of tacrine (Cognex) in Alzheimer's patients. (PubMed)

Mixed-model analysis of incomplete longitudinal data from a high-dose trial of tacrine (Cognex) in Alzheimer's patients. Mixed-model techniques are applied to incomplete longitudinal data from a double-blind, placebo-controlled, parallel-group, high-dose study of tacrine in patients with Alzheimer's disease. The study consisted of a 30-week double-blind treatment period. Patients were randomized to one of four treatment groups. Dosing was initiated at 40 mg/day and increased in increments of 40

1996 Journal of biopharmaceutical statistics

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>